The annexins are a family of about 13 proteins that bind to cellular membranes and anionic phospholipids in a Ca 2ϩ -dependent manner (1) (2) (3) . All annexins have four repeating, highly homogenous amino acid sequences (eight repeats in the case of annexin VI), known as the annexin repeat (4) . The annexin repeat contains 70 -80 conserved amino acids, in particular the highly conserved 17-amino acid endonexin fold. Each repeat comprises one compact domain that consists of five ␣-helices wound into a right-handed super-helix. The sum of the annexin repeats make up the protein core, which contains the binding sites for common annexin ligands such as Ca 2ϩ and anionic phospholipids. Preceding the protein core is the protease-sensitive N-terminal tail, which varies in sequence among annexins and is therefore thought to be of regulatory importance. There are many suggested functions of annexins including transmembrane ion transport, inhibition of phospholipase A 2 , inhibition of blood coagulation, signal transduction for differentiation and mitogenesis, regulation of cell-matrix interactions, and regulation of cell-cell adhesion (reviewed in Refs. 2 and 5-7). The in vivo functions of annexins have not been well established.
X-ray crystallographic analysis of annexin II has established in the presence of a single type II Ca 2ϩ -binding site in each of the second, third, and fourth domains and two type III Ca 2ϩ -binding sites in the first domain of the protein. Interestingly, these Ca 2ϩ -binding sites, along with the phospholipid-binding sites, are located on the convex surface of the molecule whereas the F-actin and heparin-binding sites are located on the opposite side of the molecule, on the concave surface. Annexin II is unique among the annexins in that its N-terminal 14 amino acids comprise a high affinity-binding site for a member of the S100 family of Ca 2ϩ -binding proteins, known as p11 (2) . The heterotetrameric complex formed by the interaction of the annexin II and p11 subunits is called annexin II heterotetramer (AIIt). Since the quaternary structure of AIIt is not known, the orientation or conformation of the annexin II subunits within AIIt is unknown. Therefore, it is also unclear whether or not all the Ca 2ϩ -binding sites of the annexin II subunits within AIIt are functional.
Recently, it was reported that a bacterially expressed mutant of annexin II, composed of inactivated type II Ca 2ϩ -binding sites displayed a higher Ca 2ϩ requirement for phospholipid binding. Furthermore, the inactivation of both the type II and type III Ca 2ϩ -binding sites resulted in the complete loss of phospholipid binding by the mutant annexin II (8) . It was therefore concluded that functionally intact type II and type III Ca 2ϩ -binding sites were required for the binding of phospholipid. However, these studies utilized a truncated annexin II in which the N-terminal 30 residues were removed proteolytically. It was therefore unclear if the results obtained from these studies would be applicable to the native protein. Since the truncated annexin II could not bind the p11 subunit, it was also not possible to investigate the function of the type II and type III Ca 2ϩ -binding sites of AIIt. We have previously reported the purification and character-* This work was supported by National Institutes of Health Grant RO1CA 78639 and the Alberta Heart and Stroke Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ To whom correspondence should be addressed: ization of bacterially expressed human annexin II and p11 subunits (9 (8, 10) . Consistent with Dr. Gerke's nomenclature, we have referred to these mutants as the TM, CM, and TCM mutants, respectively. These vectors originally had the mutation A65E in the annexin II sequence to provide an epitope for antibody recognition (10) . This site was reverted to the wild type sequence (E65A) in all three mutants. The mutant annexin II DNA sequences were excised from the pDS10 vector using polymerase chain reaction. The polymerase chain reaction resulted in blunt ended DNA and therefore encoded the exact sequence of wild type AIIt (11, 12) . A BamHI site was added to the 3Ј end using polymerase chain reaction with the appropriate primers. This cDNA sequence was then ligated into a NdeI-cut, Klenow filled-in, BamHI-digested pAED4.91 vector. These vectors were then transformed into Escherichia coli BL21(DE3) and grown as described previously (9) .
Purification of Recombinant Wild Type (WT), TM, CM and TCM Annexin II-After 4 h of induction with isopropyl-1-thio-␤-D-galactopyranoside, bacteria were collected by low speed centrifugation. They were subsequently sonicated in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM DTT) containing protease inhibitors. This cell lysate was then centrifuged at 100,000 ϫ g, followed by overnight dialysis against 20 mM Tris-HCl, pH 7.5, 25 mM NaCl, 1 mM DTT. The resultant cell lysate supernatant was purified by hydroxylapatite chromatography, followed by heparin affinity chromatography, and gel permeation chromatography as reported previously (9) .
Purification of Recombinant p11-The production of the recombinant p11 construct and the subsequent protein purification scheme has been previously reported (9) . Briefly, bacteria were grown and induced with isopropyl-1-thio-␤-D-galactopyranoside as described above. The resultant cell lysate supernatant was applied to Fast Q ion-exchange chromatography, the unbound flow-through was then applied to Fast S ion-exchange chromatography, followed by gel permeation chromatography.
Purification of Recombinant Annexin II Tetramer-Equimolar amounts of recombinant annexin II (WT, TM, CM, or TCM) and recombinant p11 were incubated at 4°C for 30 min and then subjected to gel permeation chromatography. Proteins were subsequently stored in buffer A at Ϫ80°C until use.
45
Ca Binding via Equilibrium Dialysis-A 300-l aliquot of either AIIt (WT, TM, CM or TCM) or annexin II (WT or TCM) at a concentration of 5 mg/ml were placed into 12-mm EDTA-treated dialysis tubing (3.5 kDa molecular mass cut-off). The dialysis tubing was placed in 100 ml of 50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM CaCl 2 , 1 mM DTT, and 4 mCi of 45 Ca for 48 h at 4°C. Radioactive counts of the solution were taken at the beginning and end of the dialysis period to ensure that 45 Ca depletion did not occur. After dialysis was completed the protein concentration of the samples was determined and aliquots of the protein samples were counted in a LKB RackBeta liquid scintillation counter.
Phospholipid Vesicle Aggregation Assay-In 12 ϫ 75-mm culture tubes, 50 l each of 20 mg/ml phosphatidylserine, phosphatidylethanolamine, and cholesterol (dissolved in chloroform) were shelled by N 2 gas. The resultant residue of lipids was resuspended in 1 ml of phospholipid aggregation buffer (30 mM HEPES, pH 7.5, 50 mM KCl) and sonicated at 75 W for three 10-s bursts with a Braun-probe sonicator to generate phospholipid vesicles at a concentration of 1 mg/ml. Phospholipid vesicle aggregation was assayed in an EL x -808 spectrophotometric plate reader (BIO-TEK Instruments) at 450 nm in a final volume of 0.200 ml.
Initially, phospholipid vesicles, either Ca 2ϩ or EGTA, and phospholipid aggregation buffer were combined resulting in a final phospholipid concentration of 0.05 mg/ml. To initiate the reaction, 10 g of AIIt (WT, TM, CM, or TCM) was added to the above mixture. Absorbance readings were taken for an additional 15 min as outlined previously (9) .
Phospholipid Vesicle Binding Assay-Following phospholipid liposomal aggregation, the reaction mixture (0.200 ml) was centrifuged at 14,000 ϫ g in a desktop centrifuge. The protein/phospholipid ratios used in the analysis ranged from 0.001 to 0.02 AIIt/phospholipid. The pellet was resuspended in 50 l of SDS disruption buffer and boiled for 3-5 min. The pellet fraction was then resolved by SDS-PAGE, stained with Coomassie Blue, and densiometric analysis of the annexin II band was performed using a Hewlett-Packard ScanJet 4c flatbed scanner and ImageQuaNT software (Molecular Dynamics).
F-actin Bundling Assay-F-actin was prepared as described previously (13) . F-actin bundling was measured by the light scattering intensity perpendicular to the incident light in a PerkinElmer Life Sciences LS-50B luminescence spectrophotometer as described previously (14) . The excitation and emission wavelengths were both set at 400 nm with 10-nm slit widths. F-actin (0.60 M) was incubated in bundling buffer (25 mM MOPS, pH 7.0, 0.5 mM DTT, 0.33 mM ATP) and varying amounts of CaCl 2 were added to the bundling assay mixture to a final volume of 0.600 ml. The bundling was initiated by the addition of WT, TM, CM, or TCM AIIt to a final concentration of 0.14 M. After a 15-min incubation at room temperature, light scattering intensity was recorded in at least triplicate. The light scattering intensity of the buffer alone was subtracted from all bundling experiments.
F-actin Binding Assay-F-actin binding was performed as described above, except that the reaction volume was adjusted to 0.200 ml. After a 15-min incubation period, the sample was centrifuged at 400,000 ϫ g for 30 min in a Beckman Optima TLX Ultracentrifuge. The pellet was solubilized overnight in 50 l of SDS disruption buffer, then boiled for 3-5 min. The pellet fraction was then resolved by SDS-PAGE, followed by densitometric analysis as described above for the phospholipid binding assay.
Plasminogen Activation Assay-The kinetics of t-PA mediated plasminogen activation were determined by measuring amidolytic activity of the plasmin generated from plasminogen as described previously (15, 16) . The reaction was performed in PG buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM CaCl 2 ) with the plasmin substrate H-D-norleucylhexahydrotyrosyl-lysine p-nitroanilide (Spectrozyme number 251) at a final concentration of 104 M, 5.6 nM t-PA, and 2.2 M WT, TM, CM, or TCM AIIt. The reaction was performed at 25°C and was initiated by the addition of varying amounts of [Glu]plasminogen. The reaction progress was monitored at 405 nm for 40 min in an EL x -808 spectrophotometric plate reader (BIO-TEK Instruments). The initial rate of plasmin formation was determined as described previously and plotted as units, where units ϭ (A 405 /min 2 ) ϫ 10 3 (16) . Fluorescence Spectroscopy -A 0.100-ml sample of WT, TM, CM, or TCM AIIt (in buffer A) was excited at 292 nm, and the emission spectra was recorded from 300 -350 nm in a PerkinElmer Life Sciences LS-50B luminescence spectrophotometer (slit widths were 10 nm). Each protein was scanned in the presence of buffer A, and rescanned following addition of 2 mM Ca 2ϩ . All measurements were collected in at least triplicate, and the max was recorded for each protein in presence of Ca 2ϩ or EGTA.
Heparin Binding Assay-Heparin binding was assessed as reported previously (17) . Briefly, AIIt was incubated with 17-kDa bovine lung heparin (Calbiochem) for 20 min in the presence of 500 M Ca 2ϩ or 10 mM EGTA, followed by high speed centrifugation at 400,000 ϫ g for 30 min in a Beckman Optima TLX Ultracentrifuge. The pellets were then resolved by SDS-PAGE, followed by densitometric analysis as described above for phospholipid binding.
Miscellaneous Techniques-Protein concentrations were determined using Coomassie Brilliant Blue, and standardizing the concentrations to bovine serum albumin, as described by Bradford (18) . All reagents used were of analytical grade or better. Data was analyzed using Sigma Plot (Jandel Scientific).
RESULTS

Mutagenesis of Annexin II and Formation of Mutant AIIt-
X-ray crystallographic analysis of annexin II has established that each of three acidic amino acid residues (Asp-161, Glu-246, and Asp-321) provide two carboxylate oxygens for the formation of three separate type II Ca 2ϩ -binding sites in domains 2, 3, and 4, respectively. Two glutamic acid residues (Glu-52 and Glu-95) are similarly involved in the formation of the two type
Function of the Ca 2ϩ -binding Sites of Annexin II Tetramer
III Ca 2ϩ -binding sites in domain 1 of the protein (8, 19) . Sitedirected mutagenesis studies of annexin II have shown that replacement of these critical acidic residues with alanine results in the inactivation of the type II and type III sites (12) . In accordance with the previous nomenclature, we have referred to these annexin II mutants as the TM mutant (type III sites inactivated), CM mutant (type II sites inactivated), and TCM mutant (type II and III sites inactivated).
WT annexin II as well as TM, CM, and TCM annexin II were expressed in our bacterial expression system and purified as described previously (9) . The elution profiles of the recombinant wild type (WT) and mutant annexin II on hydroxylapatite, heparin affinity, and gel permeation chromatography were indistinguishable (data not shown). The recombinant wild type or mutant annexin II was combined with recombinant p11 subunit and subjected to gel permeation chromatography as described previously (9) . The elution profiles, as well as the circular dichroism spectra of the recombinant WT and TM, CM, and TCM AIIt were also indistinguishable (data not shown). This suggests that a gross change in the conformation of the mutant AIIt has not occurred as a result of the mutations in the Ca 2ϩ -binding sites. (20) . As shown in Table  I requirement for the interaction of annexin II with anionic phospholipid vesicles is due to the Ca 2ϩ -dependent formation of a bridge between the amino acids of the type II Ca 2ϩ -binding sites of annexin II and the phosphoryl oxygen atoms of the phospholipid (22) . However, we found that the mutant annexin II that lacked functional type II and type III Ca 2ϩ -binding sites, TCM annexin II, both aggregated ( Fig. 1 ) and bound to anionic phospholipid vesicles in the presence of Ca 2ϩ (Fig. 1,  inset) . This observation suggested that the type II and type III Ca 2ϩ -binding sites of annexin II were not involved in the formation of a bridge between Ca 2ϩ and phospholipid. Moreover, we found that TCM annexin II bound to phospholipid in the absence of Ca 2ϩ (Fig. 1, inset) . This suggested that the amino acids of the type II and type III Ca 2ϩ -binding sites could influence the interaction of annexin II with phospholipid. Furthermore, our observation that Ca 2ϩ was required for aggregation of phospholipid by TCM annexin II (Fig. 1) provided evidence that Ca 2ϩ -binding sites other than the type II and type III sites were involved in regulating the phospholipid aggregating activity of annexin II.
Annexin (Fig. 1) , that the aggregation of phospholipid vesicles by TCM AIIt was not Ca 2ϩ -dependent (Fig. 2, A and B) . Furthermore, half-maximal aggregation of the phospholipid liposomes by TCM AIIt was similar regardless of the presence or absence of Ca 2ϩ . In the absence of AIIt, we did not observe any nonspecific phospholipid aggregation. In addition, in the absence of phospholipid vesicles, AIIt did not contribute to the turbidity nor did it pellet (data not shown). This data provided evidence that Ca 2ϩ binding at the type II and type III Ca 2ϩ -binding sites does not play a direct role in the phospholipid aggregating activity of AIIt. We also observed that the phospholipid aggregating activity of the TM and CM AIIt did not require Ca 2ϩ (Fig. 2B) , although the extent of Ca 2ϩ -independent phospholipid aggregation by TM AIIt was not as high as CM AIIt. Therefore, inactivation of either the type III (TM AIIt) or type II (CM AIIt) Ca 2ϩ -binding sites of AIIt resulted in Ca 2ϩ -independent phospholipid aggregating activity. Furthermore, since TCM AIIt did not aggregate or bind phospholipid vesicles composed of phosphatidylcholine (data not shown), it was concluded that the inactivation of the type II or type III Ca 2ϩ -binding sites of AIIt did not alter the phospholipid specificity of the protein.
We also examined the ability of the mutant AIIt to bind to phospholipid vesicles. In the presence of Ca 2ϩ , the WT, TM, CM, and TCM AIIt bound phospholipid with similar affinity and capacity (Fig. 3A) . Likewise, WT and TCM annexin II had similar binding affinities for phospholipid vesicles in the presence of Ca 2ϩ (Fig. 3, inset) . Thus, the inactivation of the type II or type III Ca 2ϩ -binding sites did not affect the affinity of annexin II or AIIt for phospholipid vesicles. However, in the presence of EGTA, all three mutant AIIt show Ca 2ϩ -independent binding to phospholipid vesicles (Fig. 3B) -dependent formation of anisotropic F-actin bundles is rapid and readily reversed by the addition of excess EGTA (14, 23) . Light scattering measurements of F-actin bundle formation by AIIt revealed that the WT and TM AIIt have an identical half-maximal Ca 2ϩ requirement for bundling (K 0.5 ϭ 287 Ϯ 12 M), whereas CM AIIt has a higher Ca 2ϩ requirement for half-maximal bundling (K 0.5 ϭ 490 Ϯ 17 M) (Fig. 4) . Moreover, TCM AIIt demonstrated Ca 2ϩ -independent F-actin bundling. Examination of the Ca 2ϩ dependence of F-actin binding by the mutant AIIt revealed that WT, TM, and CM AIIt bound to F-actin in a Ca 2ϩ -dependent manner, whereas TCM AIIt did not require Ca 2ϩ for binding to F-actin (Fig. 4, inset) . In the absence of F-actin, pelleting of AIIt was not observed (data not shown).
We also examined the F-actin binding affinity of the WT, TM, CM, and TCM AIIt. As shown in Fig. 5 , the WT and mutant AIIt showed similar binding affinity for F-actin. Likewise, the F-actin binding affinity of WT and TCM annexin II was similar (Fig. 5, inset) . Thus, the inactivation of the type II or type III 
Ca 2ϩ -binding sites did not affect the affinity of annexin II or AIIt for F-actin.
Ca 2ϩ Dependence of t-PA-dependent Plasminogen Activation-Recently our laboratory reported the dramatic stimulation of t-PA-dependent plasminogen activation by AIIt (15, 16) . We also reported that the stimulation of t-PA-dependent plasminogen activation by AIIt was Ca 2ϩ -independent. As shown in Fig. 6, the WT 
DISCUSSION
AIIt is a multifunctional protein that interacts in a Ca 2ϩ -dependent manner with anionic phospholipid, F-actin, and heparin. The binding sites for these ligands are located within the annexin II subunit of AIIt. In the present study we utilized site-directed mutagenesis to inactivate the type III (the TM mutant), type II (the CM mutant), and both type II and III Ca 2ϩ -binding sites of annexin II (the TCM mutant). The strategy for inactivation of the annexin II Ca 2ϩ -binding sites was initially proposed by Dr. Gerke's (8, 11, 12) laboratory, who confirmed that the substitution of the key acidic residue of each Ca 2ϩ -binding site with alanine resulted in the inactivation of the Ca 2ϩ -binding site. However, in contrast to that study, which utilized a chymotrypsin-digested annexin II, we generated a full-length recombinant annexin II. Therefore, for the first time, we were able to form the TM, CM, and TCM mutant forms of AIIt by combining the mutant recombinant annexin II with wild type recombinant p11 subunit. In the present report we have used these mutant forms of AIIt to examine the role of the type II and III sites of AIIt in the Ca 2ϩ -dependent interaction with phospholipid, F-actin, heparin, and plasminogen.
Since the WT and three mutant forms of annexin II had identical elution profiles after chromatography on hydroxylapatite, heparin-Sepharose, and Sephacryl S-100, we concluded that, as reported earlier, these mutations did not substantially perturb the conformation of annexin II. As well, the mutant annexin II monomers were able to bind to p11 and form AIIt, a further indication that annexin II was in its native conformation. Furthermore, since the WT recombinant AIIt and the TM, CM, and TCM mutants of AIIt had identical gel permeation chromatographic profiles and identical CD spectra, we have concluded that the TM, CM, and TCM mutants of AIIt were not conformationally compromised. The ability of the three mutants to bind heparin and stimulate t-PA-dependent plasminogen conversion to plasmin was further evidence that the conformation of these proteins was not perturbed.
Our analysis of the Ca 2ϩ -binding capacity of the WT, TM, CM, and TCM AIIt has produced several unexpected results. First, we found that in the presence of 2 mM Ca 2ϩ , WT annexin II and WT AIIt bound only about 4 or 6 mol of Ca 2ϩ /mol of AIIt, respectively. Since the crystal structure of annexin II established the presence of two type III Ca 2ϩ -binding sites and three type II Ca 2ϩ -binding sites, it was expected that annexin II should bind 5 mol of Ca 2ϩ /mol and AIIt would bind at least 10 mol of Ca 2ϩ /mol of AIIt. Previous equilibrium dialysis experiments performed in the presence of 1 mM Ca 2ϩ showed that annexin II and AIIt bound 2 and 4 mol of Ca 2ϩ bound/mol of protein, respectively (20) . One explanation for the discrepancy between the equilibrium dialysis results and the predicted results is that full occupancy of the Ca 2ϩ -binding sites may require greater than 2 mM Ca 2ϩ . However, extended incubation of AIIt in the presence of greater than 2 mM Ca 2ϩ leads to precipitation of the protein. 2 It is therefore not possible to perform equilibrium dialysis experiments at concentrations of Ca 2ϩ greater than 2 mM. It is also possible that AIIt binds less Ca 2ϩ than expected because the conformation or orientation of the annexin II subunits is such that not all Ca 2ϩ -binding sites of the annexin II subunit are functional. However, without the elucidation of the x-ray crystallographic structure of AIIt, it is not possible to evaluate this possibility.
Second, it was unexpected that the TCM annexin II and TCM AIIt bound 1 mol of Ca 2ϩ /mol and 2-3 mol of Ca 2ϩ /mol, respectively, because the x-ray crystallographic data had identified the presence of only type II and type III Ca 2ϩ -binding sites on annexin II (3, 22) . One possible explanation for this result is that the mutations introduced into annexin II do not provide total inactivation of the type II and type III Ca 2ϩ -binding sites. We feel this is unlikely because the substitution of acidic residues with alanine would result in the loss of two carboxyl After the incubation period, the samples were centrifuged at 400,000 ϫ g for 30 min, and the AIIt bound to F-actin was quantitated by densitometric analysis of SDS-PAGE as described under "Experimental Procedures." Results shown are representative of three independent experiments. Inset, concentration dependence of F-actin binding by WT and TCM annexin II monomer. Reactions were performed as described above, except that WT (filled circles) or TCM (open circles) annexin II monomer were added to initiate the reaction. After the incubation period, the samples were centrifuged at 400,000 ϫ g for 30 min, and the annexin II bound to F-actin was quantitated by densitometric analysis of SDS-PAGE as described under "Experimental Procedures." Results shown are representative of three independent experiments. FIG. 6. Stimulation of tissue plasminogen activator-mediated plasminogen activation by WT, TM, CM, and TCM AIIt. Tissue plasminogen activator (5.6 nM) was incubated at 25°C in PG buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, and 5 mM CaCl 2 ), and 104 M plasmin substrate (Spectrozyme number 251) in the presence of 2 M WT, TM, CM, or TCM AIIt. The reaction was initiated by the addition of the indicated amounts of [Glu]plasminogen. The amidolytic activity of generated plasmin was monitored by A 405 as described under "Experimental Procedures." Shown is a comparison of the rates of plasmin generation calculated from plots of A 405 versus time. 2 The plasmin generation unit is defined as (A 405 /min 2 ) ϫ 10 Ϫ3 and is expressed as mean Ϯ S.D. (n ϭ 3). 
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2ϩ is heptacoordinated by three carbonyl oxygen atoms, two oxygen atoms of the distal acidic residue, and two solvent molecules. The x-ray crystallographic structure of the annexin V-glycerophosphoserine complex has been reported and it was concluded from these studies that Ca 2ϩ forms a bridge between the amino acids of the type II Ca 2ϩ -binding sites and the phosphoryl oxygen atom of the phospholipid (22) . Furthermore, the carboxyl oxygen of the distal acidic residue of the type II Ca 2ϩ -binding sites hydrogen bonds with the serine amino group of glycerophosphoserine. It was therefore unexpected that TM and CM AIIt bound to phospholipid vesicles and even more surprising that the binding of the CM and TCM mutant was Ca 2ϩ -independent. It was also unexpected that the CM and TCM AIIt had identical affinity for phospholipid in the presence or absence of Ca 2ϩ . This is surprising because the substitution of the acidic residues of the TCM AIIt with alanine would be expected to substantially weaken the interaction of AIIt with phospholipid. This is likely to occur by preventing the interaction of the carbonyl oxygen of the distal acidic residue with the polar head group of phosphatidylserine and by preventing the interaction of Ca 2ϩ with the phosphoryl oxygen of phosphatidylserine. However, since the affinity of the WT, TM, CM, and TCM AIIt for phospholipid is identical, it is likely that these interactions are not sufficiently strong to influence the interaction of annexin II with phosphatidylserine. A detailed analysis of the mechanism of the interaction of annexin II or AIIt with phosphatidylserine will not be possible until the x-ray crystallographic structure of the phosphatidylserine-AIIt complex is elucidated.
Our results differ dramatically from those obtained by Dr. Gerke's (8, 11, 12) laboratory who reported that the TCM annexin II did not bind to phospholipid. Since the TCM annexin II mutant used in these experiments was a chymotryptic fragment that lacked the first 29 residues of the N terminus, it is possible that their protein was not in its native conformation. Drs. Drust and Creutz (24) have shown that proteolysis of the N terminus of annexin II dramatically increases the Ca 2ϩ dependence of interaction of AIIt with biological membranes.
It was also interesting that the TM and CM AIIt demonstrated Ca 2ϩ -dependent binding to F-actin. This suggested that the type II or III Ca 2ϩ -binding sites are not involved in the Ca 2ϩ -dependent interaction of AIIt with F-actin. It was therefore unexpected that the TCM AIIt showed Ca 2ϩ -independent binding to F-actin. Although speculative, it is reasonable to propose that in the absence of Ca 2ϩ , the distal acidic residues of the type II Ca 2ϩ -binding sites and the acidic residue of the type III Ca 2ϩ -binding sites interact with other residues within annexin II. This interaction results in the stabilization of a conformation of annexin II which does not allow for interaction with phospholipid or F-actin. The binding of Ca 2ϩ to the Ca 2ϩ -binding sites results in the reorientation of these acidic residues such that they can now participate in Ca 2ϩ coordination. The resulting change in the conformation also allows the interaction of annexin II with phospholipid or F-actin. Similarly, removal of these residues by site-directed mutagenesis also prevents these acidic residues from interacting with other amino acid residues and promoting the conformation of annexin II that cannot interact with phospholipid or F-actin. Validation of this experimental model will await elucidation of the x-ray crystallographic structure of AIIt. 
